We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+13.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3.57B
AUM Growth
+$553M
Cap. Flow
+$561M
Cap. Flow %
15.73%
Top 10 Hldgs %
49.57%
Holding
170
New
38
Increased
32
Reduced
29
Closed
33

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$104M
2
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$79.7M
3
ASND icon
Ascendis Pharma A/S
ASND
+$55.2M
4
YARW
Yarrow Bioscience
YARW
+$54M
5
FOLD
Amicus Therapeutics
FOLD
+$32.5M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$58.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$32.9M
3
ISRG icon
Intuitive Surgical
ISRG
+$25.4M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$24.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$24.1M

Sector Composition

Rank Sector Weight
1 Healthcare 97.46%
2 Consumer Staples 0.67%
3 Consumer Discretionary 0.06%
4 Industrials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
76
DELISTED
Molecular Templates, Inc.
MTEM
$5.79M 0.16%
48,276
– –
FOMX
77
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$5.73M 0.16%
1,117,324
– –
BIIB icon
78
Biogen
BIIB
$32.6B
$5.48M 0.15%
+20,000
New +$6.21M
NVTR
79
DELISTED
Nuvectra Corporation Common Stock
NVTR
$5.01M 0.14%
+384,600
New +$3.91M
ISRG icon
80
Intuitive Surgical
ISRG
$131B
$4.13M 0.12%
30,000
-181,755
-86% -$25.4M
ACHN
81
DELISTED
Achillion Pharmaceuticals
ACHN
$3.71M 0.1%
1,000,000
– –
IVC
82
DELISTED
Invacare Corporation
IVC
$3.48M 0.1%
200,000
– –
MRNS
83
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$3.47M 0.1%
226,933
– –
ATNX
84
DELISTED
Athenex, Inc. Common Stock
ATNX
$3.23M 0.09%
+9,500
New +$3.01M
ODT
85
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$3.18M 0.09%
150,000
– –
ALNA
86
DELISTED
Allena Pharmaceuticals
ALNA
$2.75M 0.08%
250,000
– –
ARWR icon
87
Arrowhead Research
ARWR
$12.6B
$2.63M 0.07%
+365,445
New +$2.25M
ADXS
88
DELISTED
Advaxis Inc
ADXS
$2.54M 0.07%
+100,000
New +$3.73M
AKCA
89
DELISTED
Akcea Therapeutics Inc
AKCA
$2.49M 0.07%
+97,144
New +$2.09M
SBBP
90
DELISTED
Strongbridge Biopharma plc.
SBBP
$2.43M 0.07%
275,000
– –
INCY icon
91
PUT
Incyte
INCY
$26.3B
$2.23M 0.06%
+100,000
New +$9.02M
MCK icon
92
McKesson
MCK
$106B
$2.11M 0.06%
+15,000
New +$2.34M
FRTX
93
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$1.66M 0.05%
3,628
– –
PBYI icon
94
CALL
Puma Biotechnology
PBYI
$481M
$1.61M 0.05%
200,000
+100,000
+100% +$7.49M
EIGR
95
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$1.55M 0.04%
5,256
– –
XBI icon
96
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.8B
$1.55M 0.04%
900,000
+300,000
+50% +$27.4M
ITCI
97
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.47M 0.04%
+70,000
New +$1.36M
GYRE icon
98
Gyre Therapeutics
GYRE
$708M
$1.42M 0.04%
+7,333
New +$1.37M
CSBR icon
99
Champions Oncology
CSBR
$69.2M
$1.33M 0.04%
366,973
-19,567
-5% -$73K
STLA icon
100
Stellantis
STLA
$19.8B
$1.27M 0.04%
62,000
– –
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Perceptive Advisors held 170 positions worth $3.57B, up 18% from $3.02B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Perceptive Advisors deployed $561M of net new capital in Q1 2018, opening 38 new positions and adding to 32 existing holdings. Its largest new stake was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $58.5M trimmed.

  • Perceptive Advisors's largest Q1 2018 buy was Alexion Pharmaceuticals: 873,450 shares worth $97.4M.
  • Perceptive Advisors added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2018, an estimated $79.7M increase.
  • Perceptive Advisors's biggest Q1 2018 reduction was AnaptysBio, cutting an estimated $58.5M.
  • Perceptive Advisors fully exited Zimmer Biomet in Q1 2018, selling an estimated $24.1M.
  • Perceptive Advisors's ten largest holdings make up 50% of its $3.57B portfolio in Q1 2018.
  • Perceptive Advisors opened 38 new positions and closed 33 in Q1 2018.
  • Perceptive Advisors's portfolio value rose 18% quarter-over-quarter to $3.57B.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.